We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ERLYAND, JANSSEN APALUTAMIDE (Janssen-Cilag Pty Ltd)
Product name
ERLYAND, JANSSEN APALUTAMIDE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
80 working days (255)
Active ingredients
apalutamide
Registration type
NCE/NBE
Indication
ERLYAND, JANSSEN APALUTAMIDE (tablets) is indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available